Humoral Acute Rejection in a Kidney Transplant Recipient with Idiopathic Thrombocytopenic Purpura

Figure 2

Evolution of graft function (SrCr) during antirejection treatment. Yellow arrows show plasmapheresis (days 8, 10, 12, 15, 17, and 19); green, rituximab (day 14); and purple, IG-IV treatment (days 9, 11, 13, 16, 18, and 20).